$220.9M obligated to Mapp Biopharmaceutical, Inc. by the Office of Assistant Secretary for Preparedness and Response.
HHS Office of Assistant Secretary for Preparedness and Response received $220.9M in FY2027 appropriations dedicated to procurement of therapeutics targeting Ebola, Sudan virus, and Marburg virus. The funding flows directly to MAPP Biopharmaceutical, Inc., marking a sustained commitment to countermeasure stockpiling for high-consequence hemorrhagic fevers outside existing Strategic National Stockpile protocols. This procurement authorization signals demand for late-stage therapeutic candidates and manufactured inventory in viral hemorrhagic fever treatment. Vendors with approved or Phase III filovirus antivirals, monoclonal antibody platforms, or manufacturing capacity for temperature-stable formulations face a defined contracting pathway through ASPR's medical countermeasures division. The appropriation is already enacted, placing near-term delivery expectations on existing MAPP contracts and creating adjacency opportunities for complementary diagnostics or cold-chain logistics. Watch ASPR procurement notices and MAPP contract modifications through early 2027 for follow-on therapeutic procurements or allied capability gaps in manufacturing scale-up and stability testing.